JP2020527139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527139A5 JP2020527139A5 JP2020501154A JP2020501154A JP2020527139A5 JP 2020527139 A5 JP2020527139 A5 JP 2020527139A5 JP 2020501154 A JP2020501154 A JP 2020501154A JP 2020501154 A JP2020501154 A JP 2020501154A JP 2020527139 A5 JP2020527139 A5 JP 2020527139A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 9
- 238000011282 treatment Methods 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 4
- 229960001592 paclitaxel Drugs 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 229960000578 gemtuzumab Drugs 0.000 claims 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- -1 mechloretamine Chemical compound 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 229960003989 tocilizumab Drugs 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 229960002964 adalimumab Drugs 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 208000024348 heart neoplasm Diseases 0.000 claims 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100022464 5'-nucleotidase Human genes 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 108010072524 BKT140 Proteins 0.000 claims 1
- 229940125565 BMS-986016 Drugs 0.000 claims 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 claims 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 claims 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010062038 Lip neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 229940125568 MGD013 Drugs 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 229930192392 Mitomycin Natural products 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 206010043515 Throat cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229930183665 actinomycin Natural products 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000002454 adrenal cortex cancer Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229950007843 bavituximab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229940121420 cemiplimab Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000000315 cryotherapy Methods 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims 1
- 229960002193 histrelin Drugs 0.000 claims 1
- 108700020746 histrelin Proteins 0.000 claims 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 claims 1
- 201000006866 hypopharynx cancer Diseases 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000006721 lip cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- JJVZSYKFCOBILL-MKMRYRNGSA-N motixafortide Chemical compound NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccc(F)cc1 JJVZSYKFCOBILL-MKMRYRNGSA-N 0.000 claims 1
- 201000008106 ocular cancer Diseases 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000003101 oviduct Anatomy 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229960003876 ranibizumab Drugs 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 208000037959 spinal tumor Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229950005972 urelumab Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 0 C=CC1=C*(*=C)*=C1 Chemical compound C=CC1=C*(*=C)*=C1 0.000 description 1
- ZBMLJTQPFWKJEI-UHFFFAOYSA-N Nc1nc(cc(cc2)-c3ccn[nH]3)c2c(NCc2cccnn2)c1 Chemical compound Nc1nc(cc(cc2)-c3ccn[nH]3)c2c(NCc2cccnn2)c1 ZBMLJTQPFWKJEI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762532932P | 2017-07-14 | 2017-07-14 | |
| US62/532,932 | 2017-07-14 | ||
| US201862662405P | 2018-04-25 | 2018-04-25 | |
| US62/662,405 | 2018-04-25 | ||
| US201862689412P | 2018-06-25 | 2018-06-25 | |
| US62/689,412 | 2018-06-25 | ||
| PCT/US2018/041723 WO2019014402A1 (en) | 2017-07-14 | 2018-07-12 | MODULATORS OF NLRP3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527139A JP2020527139A (ja) | 2020-09-03 |
| JP2020527139A5 true JP2020527139A5 (https=) | 2021-07-26 |
| JP7159282B2 JP7159282B2 (ja) | 2022-10-24 |
Family
ID=63036509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501154A Active JP7159282B2 (ja) | 2017-07-14 | 2018-07-12 | Ｎｌｒｐ３モジュレーター |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11344543B2 (https=) |
| EP (1) | EP3652166B1 (https=) |
| JP (1) | JP7159282B2 (https=) |
| KR (1) | KR102698385B1 (https=) |
| CN (2) | CN110914258A (https=) |
| AU (1) | AU2018301681B2 (https=) |
| BR (1) | BR112020000523A2 (https=) |
| CA (1) | CA3069524A1 (https=) |
| CL (1) | CL2020000085A1 (https=) |
| CO (1) | CO2020000227A2 (https=) |
| ES (1) | ES3002968T3 (https=) |
| IL (1) | IL271935A (https=) |
| MY (1) | MY201080A (https=) |
| NZ (1) | NZ761519A (https=) |
| PE (1) | PE20200296A1 (https=) |
| SG (1) | SG11202000248UA (https=) |
| TW (1) | TWI791556B (https=) |
| WO (1) | WO2019014402A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20210160A1 (es) | 2018-04-25 | 2021-01-26 | Innate Tumor Immunity Inc | Moduladores de nlrp3 |
| WO2020150114A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
| US12391675B2 (en) * | 2019-01-14 | 2025-08-19 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US12338228B2 (en) * | 2019-01-14 | 2025-06-24 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| EP3929185A4 (en) * | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN114555565B (zh) * | 2019-12-13 | 2024-03-05 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| CA3177261A1 (en) | 2020-04-29 | 2021-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| WO2022017408A1 (zh) * | 2020-07-22 | 2022-01-27 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4075343A (en) * | 1976-09-13 | 1978-02-21 | Pfizer Inc. | Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof |
| US4175193A (en) * | 1977-01-14 | 1979-11-20 | Pfizer Inc. | 2-Amino-3-cyano-4-hydroxyquinolines |
| JPS5390271A (en) * | 1977-01-14 | 1978-08-08 | Pfizer | Method of producing 22aminoo44hydroxyquinoline |
| US4247699A (en) * | 1979-03-14 | 1981-01-27 | Pfizer Inc. | Process for making 2-amino-4-hydroxyquinolines |
| GB8727737D0 (en) * | 1987-11-26 | 1987-12-31 | Ici Plc | Antitumour agents |
| JPH11209350A (ja) | 1998-01-26 | 1999-08-03 | Eisai Co Ltd | 含窒素複素環誘導体およびその医薬 |
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP3715280B2 (ja) * | 2001-05-21 | 2005-11-09 | エフ．ホフマン−ラ ロシュ アーゲー | ニューロペプチドｙレセプターのリガンドとしてのキノリン誘導体 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| BR0312204A (pt) * | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007022946A1 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| EP1978966A4 (en) * | 2006-01-23 | 2010-11-10 | Amira Pharmaceuticals Inc | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE |
| US7868022B2 (en) | 2006-02-06 | 2011-01-11 | Janssen Pharmaceutica Nv | 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE) |
| AR065093A1 (es) * | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2009097278A1 (en) * | 2008-01-28 | 2009-08-06 | Janssen Pharmaceutica N.V. | 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| EP2240472B1 (en) | 2008-01-29 | 2012-11-21 | Janssen Pharmaceutica NV | 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace) |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2396315B1 (en) * | 2009-02-13 | 2016-08-31 | UCB Biopharma SPRL | Quinoline derivatives as pi3k kinase inhibitors |
| EP2504330A1 (en) * | 2009-11-23 | 2012-10-03 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2011063233A1 (en) * | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| CA2788363A1 (en) | 2010-01-19 | 2011-07-28 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| US20130225524A1 (en) * | 2010-11-05 | 2013-08-29 | Deping Chai | Chemical Compounds |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015077550A1 (en) | 2013-11-22 | 2015-05-28 | University Of Kentucky Research Foundation | Arylquinoline and analog compounds and use thereof to treat cancer |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| KR102727059B1 (ko) | 2015-02-16 | 2024-11-05 | 더 유니버서티 어브 퀸슬랜드 | 설포닐우레아와 관련 화합물 및 그 용도 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US20160332971A1 (en) * | 2015-05-15 | 2016-11-17 | University Of Kentucky Research Foundation | Arylquinoline, arylquinolone and arylthioquinolone derivatives and use thereof to treat cancer |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10329257B2 (en) * | 2015-08-13 | 2019-06-25 | The Broad Institute, Inc. | Compositions and methods for treating tuberculosis |
| EP3337481B1 (en) | 2015-08-21 | 2020-11-11 | The University of Kansas | Quinoline-2-amine derivatives as human tlr8-selective agonists for increasing immune response |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| KR20180040706A (ko) | 2015-09-01 | 2018-04-20 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 면역억제 시토카인에 대해 증가된 면역 또는 저항성을 갖는 면역 세포 및 그의 용도 |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| KR20180134395A (ko) | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| CN106478621B (zh) * | 2016-09-30 | 2018-12-25 | 遵义医学院 | 喹啉或喹唑啉类衍生物、制备方法及其应用 |
| US20200039998A1 (en) | 2016-12-19 | 2020-02-06 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| EP3929185A4 (en) * | 2019-02-19 | 2023-02-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
-
2018
- 2018-07-12 US US16/629,980 patent/US11344543B2/en active Active
- 2018-07-12 BR BR112020000523-1A patent/BR112020000523A2/pt not_active Application Discontinuation
- 2018-07-12 EP EP18746537.2A patent/EP3652166B1/en active Active
- 2018-07-12 CN CN201880046886.XA patent/CN110914258A/zh active Pending
- 2018-07-12 WO PCT/US2018/041723 patent/WO2019014402A1/en not_active Ceased
- 2018-07-12 MY MYPI2020000168A patent/MY201080A/en unknown
- 2018-07-12 ES ES18746537T patent/ES3002968T3/es active Active
- 2018-07-12 AU AU2018301681A patent/AU2018301681B2/en not_active Ceased
- 2018-07-12 SG SG11202000248UA patent/SG11202000248UA/en unknown
- 2018-07-12 PE PE2020000051A patent/PE20200296A1/es unknown
- 2018-07-12 KR KR1020207003984A patent/KR102698385B1/ko active Active
- 2018-07-12 CN CN202010596091.5A patent/CN111793060B/zh active Active
- 2018-07-12 JP JP2020501154A patent/JP7159282B2/ja active Active
- 2018-07-12 CA CA3069524A patent/CA3069524A1/en active Pending
- 2018-07-12 NZ NZ761519A patent/NZ761519A/en unknown
- 2018-07-13 TW TW107124243A patent/TWI791556B/zh not_active IP Right Cessation
-
2020
- 2020-01-09 IL IL271935A patent/IL271935A/en unknown
- 2020-01-10 CL CL2020000085A patent/CL2020000085A1/es unknown
- 2020-01-10 CO CONC2020/0000227A patent/CO2020000227A2/es unknown
-
2022
- 2022-04-28 US US17/731,279 patent/US12171756B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527139A5 (https=) | ||
| JP2020508302A5 (https=) | ||
| Cascinu et al. | Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| Hof et al. | Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma | |
| Hong et al. | Induction chemotherapy in advanced squamous head and neck carcinoma with high‐dose cis‐platinum and bleomycin infusion | |
| JP2020519672A5 (https=) | ||
| JP2020510032A5 (https=) | ||
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| Sun et al. | Surgical management of cervical esophageal carcinoma with larynx preservation and reconstruction | |
| JP2022153392A5 (https=) | ||
| JP2023513297A5 (https=) | ||
| JP2021520349A5 (https=) | ||
| Reynolds et al. | Outcomes of transoral laser microsurgery for recurrent head and neck cancer | |
| JP2022519923A5 (https=) | ||
| Ghazali et al. | Sustained response of HER2-positive metastatic salivary adenocarcinoma, not otherwise specified, treated with trastuzumab | |
| JP2023515687A5 (https=) | ||
| Kolagatla et al. | Colorectal adenocarcinoma metastasis to the hard palate: An uncommon site of metastasis for a common malignancy | |
| Mituś et al. | Metaplastic breast cancer with rapidly progressive recurrence in a young woman: case report and review of the literature | |
| Copson et al. | Nasopharyngeal metastasis of breast carcinoma with HER 2 discordance: a case report. | |
| Zhu | African Journal of Pharmaceutical Sciences | |
| RU2748135C2 (ru) | СПОСОБ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ МЕСТНО-РАСПРОСТРАНЕННЫХ ФОРМ РАКА ШЕЙКИ МАТКИ IIB-IIIB(T2b-T3bN0(1)M0) СТАДИЙ | |
| Tali et al. | Comprehensive Care In Oncology | |
| Rawat et al. | Intraluminal Brachytherapy with EBRT in Unresectable Esophageal Carcinoma: A Prospective Study | |
| Das et al. | Malignant peripheral nerve sheath tumour of nose and paranasal sinuses with orbital extension | |
| Hanakawa et al. | Radiation-induced laryngeal angiosarcoma: Case report |